Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04965675 · ClinicalTrials.gov registry record · Phase 3

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

A Phase 3 study of Chronic Migraine in Children, sponsored by H. Lundbeck A/S.

Recruiting
Registry status
Phase 3
Development phase
285
Enrollment target
20
Study locations

NCT04965675 is a Phase 3 study of Chronic Migraine in Children that is actively recruiting participants, run by H. Lundbeck A/S. The registered enrollment target is 285 participants. The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04965675, a Phase 3 study of Chronic Migraine in Children, is actively recruiting participants, sponsored by H. Lundbeck A/S.

RECRUITING
Registry status
Phase 3
Development phase
285 participants
Enrollment target
20
Study locations

Study Summary

To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.

Interventions

  • DRUG Placebo
  • DRUG Eptinezumab

Study Locations (20)

Florida

  • NW FL Clinical Research Group, LLC - Gulf Breeze
  • AGA Clinical Trials - Hialeah
  • Axcess Medical Research - Loxahatchee Groves
  • University of South Florida - Tampa

Michigan

  • Michigan Head Pain and Neurological Institute - Ann Arbor
  • Michigan State University - Department of Neurology - East Lansing
  • Corewell Health Butterworth Hospital - Grand Rapids

Connecticut

  • Yale-New Haven Children's Hospital - PIN - New Haven
  • Ki Health Partners LLC DBA New England Institute for Clinical Research - Stamford

New York

  • Dent Neurosciences Research Center Incorporated - Amherst
  • North Suffolk Neurology-Commack - Commack

District of Columbia

  • Children's National Medical Center - Washington D.C.

Georgia

  • Clinical Integrative Research Center of Atlanta - Atlanta

Kentucky

  • University of Kentucky HealthCare (UKHC) Kentucky Clinic - Lexington

Maryland

  • University of Maryland - Baltimore

Trial Details

FieldValue
Enrollment Target 285 participants
Start Date 2021-06-30
Est. Completion 2026-10-31
Phase Phase 3

Sponsor

H. Lundbeck A/S

72 total trials

What the Registry Record Tells You About NCT04965675

The ClinicalTrials.gov registry entry for NCT04965675 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 285 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Migraine in Children appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04965675 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Michigan, Connecticut.

Frequently Asked Questions

What is clinical trial NCT04965675 about?

NCT04965675 is a clinical study titled "A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine". To find out if eptinezumab is better than placebo (normal saline solution) in lowering the number of days with migraine in young people ages 12 to 17 with chronic migraine.

What is the current status of trial NCT04965675?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 285 participants. The study started on 2021-06-30. Estimated completion is 2026-10-31.

What conditions does trial NCT04965675 study?

This clinical trial studies the following conditions: Chronic Migraine in Children.

What interventions are being tested in trial NCT04965675?

The interventions under investigation include: Placebo (DRUG), Eptinezumab (DRUG).

Who is sponsoring clinical trial NCT04965675?

This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04965675 being conducted?

This trial has 20 study locations across Connecticut, District of Columbia, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.